Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
Status:
Recruiting
Trial end date:
2038-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the
prevention of allograft rejection following immunosuppression withdrawal in liver
transplantation. QEL-001 is a product made from a liver transplant recipient's own immune
cells, which are genetically modified and designed to help the transplant recipient's body
accept their donated liver and prevent their immune system from rejecting it.